Nemetschek AG O.N. (NEM)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 75.70 |
|---|---|
| 52-week range | 50.45 – 105.10 |
| Return, 1 month / 3 months | +21.2% / +40.4% |
| Return, 1 year / 3 years | −26.3% / +23.8% |
| Trend | Uptrend |
| RSI (14) | 69 |
| Volatility (1 year) | 47.9% |
| Worst drawdown (1 year) | -48.9% |
| Average daily value traded | 15.66M EUR |
| Dividend yield | 0.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nemetschek is a German software company that develops design and building information modelling tools for architects, engineers and construction professionals. Its products, sold under brands such as Allplan, Graphisoft and Vectorworks, support architectural design, structural engineering, facilities management and media production. Customers range from small design studios to large construction firms and public organisations. The company is based in Munich and serves customers across Europe and other regions of the world.
Nemetschek AG O.N. trades under the code NEM on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nemetschek AG O.N. (NEM) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 75.70 on 23 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 338 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 26.3% and over the last three months it rose 40.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 18.5% | ||
| From 52-week high | -27.8% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 40.4% | ||
| 6-month return | 18.5% | ||
| 12-month return, skipping the last month | -39.2% | ||
| Stability (higher is calmer) | 23 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 47.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -48.9% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 15.66M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 33 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.9% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.9% |
|---|---|
| 1 month | +21.2% |
| 3 months | +40.4% |
| 6 months | +18.5% |
| 1 year | −26.3% |
| 3 years | +23.8% |
| 5 years | −20.4% |
Signals
| 50-day / 200-day average | 65.33 / 63.86 |
|---|---|
| Golden / death cross (60 days) | Golden, 3 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.76 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 May 2026 | EUR 0.6800 |
| 21 May 2025 | EUR 0.5500 |
| 24 May 2024 | EUR 0.4800 |
| 24 May 2023 | EUR 0.4500 |
| 13 May 2022 | EUR 0.3900 |
| 13 May 2021 | EUR 0.3000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.